Hospital Admissions, Transfers and Costs of Guillain-Barré Syndrome
- PMID: 26859880
- PMCID: PMC4747559
- DOI: 10.1371/journal.pone.0143837
Hospital Admissions, Transfers and Costs of Guillain-Barré Syndrome
Abstract
Background: Guillain-Barré syndrome (GBS) has a highly variable clinical course, leading to frequent transfers within and between hospitals and high associated costs. We defined the current admissions, transfers and costs in relation to disease severity of GBS.
Methods: Dutch neurologists were requested to report patients diagnosed with GBS between November 2009 and November 2010. Information regarding clinical course and transfers was obtained via neurologists and general practitioners.
Results: 87 GBS patients were included with maximal GBS disability score of 1 or 2 (28%), 3 or 4 (53%), 5 (18%) and 6 (1%). Four mildly affected GBS patients were not hospital admitted. Of the 83 hospitalized patients 68 (82%) were initially admitted at a neurology department, 4 (5%) at an ICU, 4 (5%) at pediatrics, 4 (5%) at pediatrics neurology and 3 (4%) at internal medicine. Median hospital stay was 17 days (IQR 11-26 days, absolute range 1-133 days). Transfers between departments or hospitals occurred in 33 (40%) patients and 25 (30%) were transferred 2 times or more. From a cost-effectiveness perspective 21 (25%) of the admissions was suboptimal. Median costs for hospital admission of GBS patients were 15,060 Euro (IQR 11,226-23,683). Maximal GBS disability score was significantly correlated with total length of stay, number of transfers, ICU admission and costs.
Conclusions: Hospital admissions for GBS patients are highly heterogeneous, with frequent transfers and higher costs for those with more severe disease. Future research should aim to develop prediction models to early identify the most cost-effective allocation in individual patients.
Conflict of interest statement
Figures


Similar articles
-
Economic cost of Guillain-Barré syndrome in the United States.Neurology. 2008 Jul 1;71(1):21-7. doi: 10.1212/01.wnl.0000316393.54258.d1. Neurology. 2008. PMID: 18591502
-
Characteristics and outcomes of patients with Guillain-Barré syndrome who were admitted to the intensive care unit: a retrospective observational study.J Int Med Res. 2024 Dec;52(12):3000605241306655. doi: 10.1177/03000605241306655. J Int Med Res. 2024. PMID: 39719074 Free PMC article.
-
Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin.J Clin Neurosci. 2007 Jul;14(7):625-9. doi: 10.1016/j.jocn.2006.03.020. J Clin Neurosci. 2007. PMID: 17532498
-
Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).Presse Med. 2013 Jun;42(6 Pt 2):e193-201. doi: 10.1016/j.lpm.2013.02.328. Epub 2013 Apr 28. Presse Med. 2013. PMID: 23628447 Review.
-
Guillain-Barré syndrome--a patient guide and nursing resource.Axone. 2001 Jun;22(4):16-24. Axone. 2001. PMID: 14621501 Review.
Cited by
-
Neurological complications associated with emerging viruses in Brazil.Int J Gynaecol Obstet. 2020 Jan;148 Suppl 2(Suppl 2):70-75. doi: 10.1002/ijgo.13050. Int J Gynaecol Obstet. 2020. PMID: 31975402 Free PMC article.
-
Predictors of discharge to home/community following inpatient-rehabilitation in a US national sample of Guillain-Barre-Syndrome patients.PLoS One. 2023 May 25;18(5):e0286296. doi: 10.1371/journal.pone.0286296. eCollection 2023. PLoS One. 2023. PMID: 37228065 Free PMC article.
-
Detection of Herpesviruses (Predominantly HHV-6) in Patients with Guillain-Barré Syndrome.Biomedicines. 2025 Apr 1;13(4):845. doi: 10.3390/biomedicines13040845. Biomedicines. 2025. PMID: 40299442 Free PMC article.
-
A retrospective analysis of the clinical profile and factors associated with mortality and poor hospital outcomes in adult Guillain-Barre syndrome patients.Sci Rep. 2024 Jul 5;14(1):15520. doi: 10.1038/s41598-024-65265-0. Sci Rep. 2024. PMID: 38969647 Free PMC article.
-
Explaining Pathogenicity of Congenital Zika and Guillain-Barré Syndromes: Does Dysregulation of RNA Editing Play a Role?Bioessays. 2019 Jun;41(6):e1800239. doi: 10.1002/bies.201800239. Epub 2019 May 20. Bioessays. 2019. PMID: 31106880 Free PMC article.
References
-
- Hughes RA, Cornblath DR. Guilain-Barre syndrome. Lancet. 2005. November;366(9497):1653–66. - PubMed
-
- Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barre syndrome. J Infect Dis. 1997. December;176 Suppl 2:S92–8. - PubMed
-
- Van der Meché FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992. April;326(17):1123–9. - PubMed
-
- Hughes RA, Swan AV, Raphaël JC, Annane D, Van Koningsveld R, Van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007. September;130(Pt 9):2245–57. - PubMed
-
- Van Koningsveld R, Van Doorn PA, Schmitz PI, Van der Meché FG. Changes in referral pattern and its effect on outcome in patients with Guillain-Barré syndrome. Neurolgy. 2001. February;56(4):564–6. - PubMed
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical